Considering our finding that the frequency of CDKN2A/B loss was high in PCNSL (67.9%) and PTL (55.6%), which are characterized by high frequencies of MYD88L265P and CD79B gene mutations, the authors consider that CDKN2A/B loss is likely a component of the same mutational signature that includes MYD88 and CD79B mutations. Here, MYD88 is linked to primary central nervous system lymphoma.